Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/26/2025

Treatment Options for Phantom Limb Pain

Pharmacological Treatment Options

  • The American College of Cardiology recommends first-line treatment for phantom limb pain with gabapentin or pregabalin, which have demonstrated efficacy in reducing pain intensity compared to placebo 1
  • The American Heart Association suggests the use of tricyclic antidepressants (TCAs) like nortriptyline or desipramine, or selective serotonin norepinephrine reuptake inhibitors (SSNRIs) like duloxetine or venlafaxine for phantom limb pain management 1
  • Topical agents like lidocaine 5% patches may provide relief when applied to the residual limb, with studies showing improvement in pain with minimal systemic absorption 2
  • The American College of Cardiology recommends the use of topical combinations like amitriptyline 1-2% compounded with ketamine 0.5-5% for pain management, with a 75% improvement rate when applied up to 3 times daily 2
  • Opioids may be considered for acute phantom limb pain or episodic exacerbations, but should be used cautiously due to risks of dependency, addiction, and hyperalgesia 1, 3

Non-pharmacological Approaches

  • Spinal cord stimulation may be considered for refractory cases of phantom limb pain, though evidence supporting its use is limited 4
  • Exercise therapy promotes systemic adaptation through reduction of inflammation and improvement of cardiovascular fitness 4, 5
  • Cognitive behavioral therapy helps address psychological aspects of chronic pain 3

Important Considerations

  • Tricyclic antidepressants (TCAs) should be used with caution in patients with cardiac disease or ventricular conduction abnormalities, with dosages preferably kept below 100mg/day 1
  • Avoid splinting of the residual limb as it may increase focus on the area, promote accessory muscle use, and lead to muscle deconditioning 6

Special Populations

  • Patients with cardiovascular risk factors should use TCAs with caution, and consider SSNRIs as alternatives 1
  • Patients with a history of substance abuse should emphasize non-opioid and non-pharmacological approaches 3